Abstract LB031: SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles

旁观者效应 曲妥珠单抗 医学 癌症研究 药理学 乳腺癌 化学 癌症 内科学 免疫学
作者
Ting Zhang,Lingfeng You,Jianyan Xu,Junzhao Yin,Bolei Qu,Yuchang Mao,Beibei Fu,Dan Cao,Linda Zhao,Jun Feng,Min Hu,Feng He
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (8_Supplement): LB031-LB031 被引量:6
标识
DOI:10.1158/1538-7445.am2023-lb031
摘要

Abstract Current clinical HER2-targeting ADCs, especially T-DXd, have shown strong efficacy in HER2-expressing/mutant cancers, however, with adverse events such as hematologic toxicities and interstitial lung disease (ILD)/pneumonitis. Here we presented a potential best-in-class HER2-directed ADC, SHR-A1811, which was composed of trastuzumab, a stable and cleavable linker, and a novel topoisomerase I inhibitor payload (SHR9265). SHR9265 was a delicately selected exatecan derivative with a better liposolubility and cellular permeability: SHR9265 had a higher AlogP value than SHR7971, synthesized using published DXd structure (3.67 vs. 2.72). Consistently, SHR9265 showed ~5 times higher membrane permeability (PAMPA model) at pH5 and pH7.4. Cell killing activity of SHR9265 was ~3 times more potent than SHR7971. SHR-A1811 had a drug-to-antibody ratio (DAR) of 5.7, and showed HER2-dependent growth inhibition against various breast cancer and gastric cancer cell lines. In the bystander killing system, SHR-A1811 was able to kill both SK-BR-3 (HER2+) and MDA-MB-468 (HER2-) cells when co-cultured, with the IC50 on MDA-MB-468 of 0.28 nM. The in vitro efficacy of SHR-A1811 was comparable with anti-Her2-SHR9265 (DAR 7.5) and ADC1 (synthesized using T-DXd structure), and stronger than anti-Her2-SHR9265 (DAR 3.5). In SK-BR-3 (HER2 high), JIMT-1 (HER2 moderate) and capan-1 (HER2 low) xenograft models, SHR-A1811 treatment resulted in a dramatic and sustained inhibition of tumor growth. A significantly stronger antitumor activity was observed for SHR-A1811 than ADC1 under the same dosages. Moreover, SHR-A1811 showed good stability and improved safety profiles, presumably due to the proper steric hindrance which was purposely designed on the payload (SHR9265). Less than 2% of payload release was observed in human plasma after a 21-day incubation. The HNSTD of SHR-A1811 in cynomolgus monkeys was 40mpk with thymus as the main target organ. No death and lung lesions were observed at dose levels up to 70mpk for 42 days, while ADC1 led to one male cynomolgus monkey death on day 10 at 70mpk with multiple lung damages. These findings were consistent with safety profiles observed in a multi-center, dose-escalation phase I clinical trial (NCT0444620). Patients with different solid tumor types received initial intravenous doses of SHR-A1811 from 1 to 8.0 mg/kg. Only trace amount of free toxin was detected. The Cmax of payload was 3.85 ng/ml at 8mg/kg of SHR-A1811. The incidence of G2 ILD was < 2.5% and the treatment discontinuation rate was 5.1% across doses. In summary, with a highly permeable payload, optimized DAR, great potency and better clinical safety profiles, SHR-A1811 has demonstrated the best-in-class potential. Currently SHR-A1811 has entered phase II and phase III clinical studies for breast cancer, gastric cancer, colorectal cancer, and NSCLC (NCT05424835, NCT05482568, NCT04818333, NCT05349409). Citation Format: Ting Zhang, Lingfeng You, Jianyan Xu, Junzhao Yin, Bolei Qu, Yuchang Mao, Beibei Fu, Dan Cao, Linda Zhao, Jun Feng, Min Hu, Feng He. SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr LB031.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
略略略完成签到,获得积分10
刚刚
myyyyy完成签到 ,获得积分10
1秒前
Dky_安静的初夏应助hhh采纳,获得10
1秒前
两只棚猫完成签到,获得积分10
1秒前
66完成签到,获得积分10
2秒前
DJ完成签到,获得积分10
2秒前
ZSJ完成签到,获得积分10
3秒前
不低头完成签到,获得积分10
4秒前
4秒前
强健的冰棍完成签到,获得积分10
4秒前
LL完成签到,获得积分10
4秒前
蔚岚影落完成签到,获得积分10
4秒前
暴躁的问兰完成签到 ,获得积分10
5秒前
yar应助大蓝蓝放电水母采纳,获得30
5秒前
感动代双完成签到 ,获得积分10
5秒前
5秒前
Luck完成签到 ,获得积分10
5秒前
6秒前
djh完成签到,获得积分10
6秒前
牛奶拌可乐完成签到 ,获得积分10
7秒前
124cndhaP完成签到,获得积分10
7秒前
8秒前
aaaaaa发布了新的文献求助10
8秒前
甘博完成签到,获得积分10
8秒前
打工人完成签到,获得积分10
9秒前
guohuameike完成签到,获得积分10
9秒前
Nancy完成签到,获得积分10
9秒前
qingqing168完成签到,获得积分10
11秒前
ilmiss发布了新的文献求助10
11秒前
水濑心源发布了新的文献求助10
11秒前
毛毛哦啊完成签到,获得积分10
11秒前
坐忘道发布了新的文献求助10
12秒前
Seiswan完成签到,获得积分10
12秒前
明亮的泥猴桃完成签到,获得积分10
12秒前
嘉星糖完成签到,获得积分10
13秒前
13秒前
科研大熊猫完成签到,获得积分10
13秒前
14秒前
酷酷的乐菱完成签到,获得积分10
14秒前
yoyo20012623完成签到,获得积分10
15秒前
高分求助中
Nickel, Cobalt and Palladium Catalysed Infarction with Ventricular following rich structural diversity 1000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968608
求助须知:如何正确求助?哪些是违规求助? 3513486
关于积分的说明 11168243
捐赠科研通 3248926
什么是DOI,文献DOI怎么找? 1794540
邀请新用户注册赠送积分活动 875188
科研通“疑难数据库(出版商)”最低求助积分说明 804676